603676.SH
卫信康
SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
CNY 9.14
−2.04%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
11.0x
Market Cap
CNY 3.98B
MomentumView details →
1D Return
−2.04%
YTD Return
−13.69%
RSI (14)
47.5
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
11.0x
Market Cap
CNY 3.98B
RSI (14)
47.5
MomentumView details →
1D Return
−2.04%
YTD Return
−13.69%
Similar companies
Latest newsMore news →
Weixin Kang's wholly-owned subsidiary Yangpu Jingtai Pharmaceutical received approval from China's National Medical Products Administration for a supplementary application for Potassium Aspartate Injection, adding a new specification and deemed to pass consistency evaluation.4d agoWeixinkang announced its 2026 first-half results: net profit attributable to shareholders was 143 million yuan, down 21.81% year-on-year.8d ago